Mr. Gary Thompson reports

M PHARMACEUTICAL INC. ANNOUNCES STRATEGY TO SEEK DISTRIBUTION PARTNERS FOR THEIR PATENTED TECHNOLOGIES TO DELIVER PHYTOESTROGENS FOR THE TREATMENT OF THE SYMPTOMS OF MENOPAUSE

M Pharmaceutical Inc., as part of its planned acquisition of 40 J's, will immediately seek marketing and distribution partnerships for the patented and proprietary topical products for the relief of menopausal symptoms that will be part of the assets being acquired. There are approximately 65 million women in North America currently nearing or experiencing menopause.

"Menopause is a natural occurrence in women brought about by the decline of the secretion of hormones by a women's body. In many instances, hormone replacement therapy (HRT) is a standard medical treatment for these symptoms, but the strong synthetic hormones prescribed for HRT often lead to many undesirable side effects," said Gary Thompson, president and chief executive officer of M Pharmaceutical USA.

"Our product's innovative topical formulation of menthol and L-arginine, paired with other key, naturally occurring phytoestrogens, has been shown to improve the symptoms of menopause without the unwanted side effects sometimes associated with standard HRT treatments. Our goal is to have distribution contracts in place and product shipping by midsummer."

Formed in early 2015, M Pharmaceutical is a clinical-stage company developing innovative technologies for obesity and weight management. In addition to its recent acquisition of C-103, a reformulation of orlistat from Chelatexx LLC, the company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights. The company has also recently acquired a Food and Drug Administration-cleared fertility product branded as ToConceive that represents its first offering in the women's health field.

We seek Safe Harbor.